In today’s recent session, 1.76 million shares of the Novo Nordisk ADR (NYSE:NVO) have been traded, and its beta is 0.66. Most recently the company’s share price was $70.38, and it changed around $1.06 or 1.52% from the last close, which brings the market valuation of the company to $236.90B. NVO at last check was trading at a discount to its 52-week high of $143.69, offering almost -104.16% off that amount. The share price’s 52-week low was $57.00, which indicates that the recent value has risen by an impressive 19.01% since then. We note from Novo Nordisk ADR’s average daily trading volume that its 10-day average is 8.4 million shares, with the 3-month average coming to 10.22 million.
Novo Nordisk ADR stock received a consensus recommendation rating of Hold, based on a mean score of 2.03. If we narrow it down even further, the data shows that 1 out of 13 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 5 recommended NVO as a Hold, whereas 4 deemed it a Buy, and 1 rated it as Underweight.
Novo Nordisk ADR (NYSE:NVO) trade information
Instantly NVO has been showing a green trend so far today with a performance of 1.52% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 70.42 on recent trading dayincreased the stock’s daily price by 0.06%. The company’s shares are currently down -49.32% year-to-date, but still up 1.97% over the last five days. On the other hand, Novo Nordisk ADR (NYSE:NVO) is -3.13% down in the 30-day period. We can see from the shorts that 26.61 million shares have been sold at a short interest cover period of 2.65 day(s).
The consensus price target as assigned by Wall Street analysts is $158, which translates to bulls needing to increase their stock price by 55.46% from its current value. Analyst projections state that NVO is forecast to be at a low of $156 and a high of $160.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 21.74%. Novo Nordisk ADR earnings are expected to increase by 28.13% in 2025, but the outlook is positive 18.77% per year for the next five years.
NVO Dividends
Novo Nordisk ADR’s next quarterly earnings report is expected to be released on 2025-May-07. The annual dividend yield of the stock is 2.36 percent and its annual dividend per share was 1.66. It is important to note, however, that the 2.36% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision. The average dividend yield for the past five years averaged 1.46 per year.
Novo Nordisk ADR (NYSE:NVO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.01% of Novo Nordisk ADR shares, and 9.85% of them are in the hands of institutional investors. The stock currently has a share float of 9.85%. Novo Nordisk ADR stock is held by 1789.0 institutions, with JENNISON ASSOCIATES LLC being the largest institutional investor. By 2024-06-30, it held 0.476% of the shares, which is about 21.22 million shares worth $3.03 billion.
FMR LLC, with 0.4373% or 19.49 million shares worth $2.78 billion as of 2024-06-30, holds the second largest percentage of outstanding shares.
HARBOR FUNDS-Harbor Capital Appreciation Fund and Bridge Builder Trust-Bridge Builder Large Cap Growth Fund were the top two Mutual Funds as of Apr 30, 2025 . The former held 4.11 shares worth $289.3 million, making up 0.12% of all outstanding shares. On the other hand, Bridge Builder Trust-Bridge Builder Large Cap Growth Fund held roughly 3.37 shares worth around $237.35 million, which represents about 0.10% of the total shares outstanding.
